Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer.
Dose-escalated EBRT is associated with improved overall survival in men with intermediate- and high-risk prostate cancer but not low- risk prostate cancer, and this results add to the evidence questioning aggressive local treatment strategies inMen with low-risk Prostate cancer but supporting such treatment in Men with greater disease severity.
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
- A. Kalbasi, Chad A. Komar, +5 authors G. Beatty
- Biology, MedicineClinical Cancer Research
- 28 June 2016
PDAC responds to radiotherapy by producing CCL2, which recruits Ly6C+CCR2+ monocytes to support tumor proliferation and neovascularization after radiotherapy, which holds promise for improving radiotherapy efficacy in PDAC.
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Early data demonstrate that the combination of pembrolizumab with intratumoral SD-101 is well tolerated and can induce immune activation at the tumor site, which can potentially increase clinical efficacy with minimal additional toxicity relative to PD-1 blockade alone.
Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles.
- Katie M. Campbell, Gabriela Steiner, Daniel K. Wells, A. Ribas, A. Kalbasi
- Biology, MedicinebioRxiv : the preprint server for biology
- 1 April 2020
A publicly accessible database of epitopes predicted to bind any class I HLA protein across the entire SARS-CoV-2 proteome is generated and evidence is shown that these previously validated epitopes may be relevant in other HLA contexts.
Tumour-intrinsic resistance to immune checkpoint blockade
How tumour cells can resist immune checkpoint blockade, for example, by resistance to interferon signalling and through immune-evasive oncogenic signalling pathways is described.
Radiation and immunotherapy: a synergistic combination.
Preclinical data indicate that RT can potentiate the systemic efficacy of immunotherapy, while activation of the innate and adaptive immune system can enhance the local efficacy of RT.
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
The magnitude of the antitumor T cell response and the corresponding downstream IFN-γ signaling are the main drivers of clinical response or resistance to immune checkpoint blockade therapy.
PAK4 inhibition improves PD-1 blockade immunotherapy.
It is shown that p21-activated kinase 4 (PAK4) is enriched in non-responding tumor biopsies with low T cell and dendritic cell infiltration and a lack of response to PD-1 blockade, which could be reversed with PAK4 inhibition.
CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
- A. Kalbasi, E. Fonsatti, +9 authors A. Ribas
- Biology, MedicineJournal of immunotherapy
- 1 October 2010
Direct exposure to a CD40-activating antibody does not lead to antitumor activity in melanoma cell lines, suggesting that the antitumors effects of these antibodies in the clinic may be indirectly mediated.